<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343181">
  <stage>Registered</stage>
  <submitdate>12/07/2011</submitdate>
  <approvaldate>14/07/2011</approvaldate>
  <actrnumber>ACTRN12611000735954</actrnumber>
  <trial_identification>
    <studytitle>Does exogenous glucose-dependent insulinotropic polypeptide (GIP) in combination with glucagon-like peptide-1 (GLP-1) attenuate the glycaemic response to small intestinal nutrient in critically ill patients?</studytitle>
    <scientifictitle>The effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) in combination with glucagon-like peptide-1 (GLP-1) on glycaemia in critically ill patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Blood Glucose</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Study Drug: Glucose-dependent insulinotropic polypeptide (GIP)at 2pmol.kg.min &amp; glucagon-like peptide-1 (GLP-1)  at 1.2pmol.kg.min 
Infused intravenously from 0-270mins
or 
Control: 0.9% saline &amp; GLP-1 at 1.2pmol/kg/min
Infused intravenously from 0-270mins
Patients will be studied on consecutive days (i.e. 24 hour washout period)</interventions>
    <comparator>Cross-over study - Subjects will received both study drug and control in a randomised fashion on consecutive days

The control is 0.9% saline &amp; GLP-1 at 1.2pmol/kg/min</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether the addition of exogenous glucose-dependent insulinotropic polypeptide (GIP) to glucagon-like peptide-1 (GLP-1) has a glucose-lowering effect in critically ill patients (as measured by area under the curve)</outcome>
      <timepoint>Blood glucose will be measured at 15min intervals between t=0-270min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To establish if exogenous GIP, with concurrent GLP-1 has an additive insulinotropic effect in the critically ill.</outcome>
      <timepoint>Plasma Insulin measured at t=0, 30, 60, 90, 120, 150, 210 and 270 min</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Mechanically ventilated critically ill patients.
Suitable for, or receiving post-pyloric nutrition.
Likely to stay ventilated for at least 48 hours.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>A history of diabetes.
Pregnancy.
Contraindication to placement of a post-pyloric feeding tube or enteral feeding.
Previous surgery on the small intestine.
Any gastrointestinal surgery during their current hospital admission.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients admitted to the Intensive Care Unit (ICU) of the Royal Adelaide Hospital will be screened. Next of kin will be approached for informed consent.
Study drug ,synthetic GIP and GLP-1 and placebo 0.9% saline and synthetic GLP-1 will be reconstituted by the Royal Adelaide Hospital Department of Pharmacy, as a solution in 4% albumin. Randomisation will be performed by the Department of Pharmacy, so that on each study day the investigators receive the study drug in a glass bottle coved by black plastic, therefore allocation concealment is maintained.</concealment>
    <sequence>Computer sequence generation by the department of pharmacy.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/08/2011</anticipatedstartdate>
    <actualstartdate>25/08/2011</actualstartdate>
    <anticipatedenddate>1/08/2012</anticipatedenddate>
    <actualenddate>19/04/2012</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Adam Deane</primarysponsorname>
    <primarysponsoraddress>Intensive Care Unit
Level 4, Royal Adelaide Hospital
North Terrace 
Adelaide
SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Viertel Charitable Foundation - Sylvia and Charles Viertel Charitable Foundation</fundingname>
      <fundingaddress>ANZ Trustees
GPO Box 389D 
Melbourne 
Victoria 3001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to establish if exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 (both hormones released from the gastrointestinal tract) has a glucose lowering effect in critically ill patients</summary>
    <trialwebsite />
    <publication>The results from this study were presented at the ADA conference in Chicago and published in an international medical journal.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committe</ethicname>
      <ethicaddress>Level 3
Hanson Institute
Royal Adelaide Hospital
North Terrace 
Adelaide
SA 5000</ethicaddress>
      <ethicapprovaldate>31/03/2010</ethicapprovaldate>
      <hrec>090819</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Adam Deane</name>
      <address>Intensive Care Unit
Royal Adelaide Hospital
North Terrace 
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adam Deane</name>
      <address>Intensive Care Unit
Royal Adelaide Hospital
North Terrace 
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adam Deane</name>
      <address>Intensive Care Unit
Royal Adelaide Hospital
North Terrace 
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adam Deane </name>
      <address>ICU Research 
Royal Adelaide Hospital
North Terrace
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>